Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @NektarNews
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NektarNews
-
Our collaboration with leading research institutions like
@UCLAJCCC provide valuable insight as we work toward developing novel therapies to fight#cancer.#WorldCancerDay
https://bit.ly/31Br9yV Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
On
#WorldCancerDay
we thank the patients and physicians for their collaboration and participation in clinical trials, moving us closer to our common goal: curing #cancer. Nektar is committed to bringing hope to people with cancer by creating new medicines to treat this disease.pic.twitter.com/SqzTgCOBG3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New research published with
@SpringerNature in@NatureComms from researchers@MDAndersonNews: Results show how bempeg works synergistically with multiple immune-based therapies to enhance T-cell-mediated tumor control. Click here to read: https://rdcu.be/b004j pic.twitter.com/qIof9IKmzP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New research published with
@SpringerNature in@NatureComms from the team at Antoni Ribas’ Lab@UCLAJCCC: ACT therapy supported by bempeg increases the proliferation, homing and persistence of anti-tumor T cells in melanoma models. Click here to read: http://l.ead.me/bbPfmd pic.twitter.com/5Eh77Vky10
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Nikhil Munshi
@DanaFarber discusses his research on NKTR-255 in multiple myeloma. https://youtu.be/QcRu2Rp-N_4 via@YouTubeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar Therapeutics proslijedio/la je Tweet
New sponsors of
#EBC20 trek, Climb to Fight Cancer, Mar. 19-Apr. 4, 2020. Thanks to@Servier and@NektarNews! Team now stands at 14 members. Room for 2 more people. Curious? Learn more about@climbtofight at 4:15pm Tues at Parc 55, Level 4, Davidson.https://informaconnect.com/biotech-showcase/agenda/3#workshops-and-panels-3_climb-to-fight-cancer-give-back-to-science-and-build-your-network-parc-55 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar is proud to welcome Dr. Myriam Curet to our Board of Directors. http://l.ead.me/bbMQqE pic.twitter.com/iWfUXL5Kfc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Rodríguez-Abreu presents the Phase 1/2 PROPEL study design at
#ESMOImmuno19.@myESMO View the poster: http://l.ead.me/bbLhr5 pic.twitter.com/6WNcCX6Ho0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Yesterday, at
#ASH19, Dr. Nina Shah presented a first-look at the trial design for our Phase 1 dose-escalation study of our IL-15 receptor agonist in relapsed/refractory non-Hodgkin#lymphoma and multiple#myeloma. Learn more here: http://l.ead.me/bbL2qz$NKTRpic.twitter.com/MxcBEzKEc5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar’s Head of Research, Dr. Loui Madakamutil, with Dr. Rafael Fernandez from Dr. Nikhil Munshi’s lab
@DanaFarber presenting new preclinical data at#ASH19. View the poster: http://l.ead.me/bbL2qC pic.twitter.com/uDyjysVQwQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Clinical investigators, Dr. Nina Shah
@UCSFCancer and Dr. Alan Tan@CancerCenter, present the Phase 1 study design for NKTR-255 at#ASH19@ninashah33@alantanmd View the poster: http://l.ead.me/bbL2qz pic.twitter.com/zwxZWxEuhG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us today for a presentation of our investigational therapy in collaboration with Nikhil Munshi’s lab at
@DanaFaber for multiple#myeloma at#ASH19 in Hall B, Level 2 at 6:00 pm ET. Learn more: http://l.ead.me/bbL2qC$NKTRpic.twitter.com/7WWo4uKvMb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar's Takahiro Miyazaki and Dr. Mario Marcondes with Dr. Cassie Chou of
@FredHutch as she presents new preclinical data at#ASH19 on combining NKTR-255 with CD19 CAR T immunotherapy. View the poster: http://l.ead.me/bbIFhZ pic.twitter.com/Nkt07bcGwT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#ASH19? Join us at 6 p.m. ET in Hall B to see our latest preclinical data, in collaboration with Cameron Turtle’s lab at@FredHutch, on our investigational IL-15 receptor agonist in combination with a CD19#CART immunotherapy. Learn more here: http://l.ead.me/bbIFhZ$NKTRpic.twitter.com/2QjsHYdTf1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar is proud to partner with
@CancerCenter on our Phase 1 Study of NKTR-255: Cancer Treatment Centers of America Continues Pioneering Efforts in Immuno-Oncology; Doses First Patient in Novel Immunotherapy Clinical Trial Learn more:http://l.ead.me/bbLlZpHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Yesterday our Chief R&D Officer, Jonathan Zalevsky, PhD, presented at the
#JEFHEALTHCARE19 conference. Click here to view the presentation: https://bit.ly/2Oa3rog$NKTRpic.twitter.com/D8jJaacIyr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today at
#PEGSEurope, our Head of Research, Loui Madakamutil, PhD, presented preclinical data for our investigational IL-15 receptor agonist and its potential benefits for#CART therapies. Read more here: https://bit.ly/33JPuCB pic.twitter.com/wW8m7HDQlB
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our head of in vivo pharmacology, Dr. Saul Kivimäe, presented on our investigational TLR agonist, NKTR-262, in combination with our investigational
#immunotherapy bempegaldesleukin in solid tumors at the 11th Annual#PEGSEurope. Learn more here: https://bit.ly/36ZQSTM pic.twitter.com/YVPCAqOiKm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today at
#ACR19, we shared data on our investigational regulatory T cell stimulator in development with@LillyPad for the treatment of#autoimmune & other chronic#inflammatory conditions. Learn more: https://bit.ly/2X8vibi pic.twitter.com/H5FP2E6K2E
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This weekend at
#SITC2019, Dr. Leo Nissola presented PORTER, a study evaluating the potential of biomarkers and immunotherapy combinations, including our I-O candidate, for the treatment of metastatic castration-resistant#prostatecancer. Read more here: https://bit.ly/32usK8m pic.twitter.com/VmnELvzeBP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.